PE20240593A1 - COMBINATION THERAPIES - Google Patents

COMBINATION THERAPIES

Info

Publication number
PE20240593A1
PE20240593A1 PE2023003030A PE2023003030A PE20240593A1 PE 20240593 A1 PE20240593 A1 PE 20240593A1 PE 2023003030 A PE2023003030 A PE 2023003030A PE 2023003030 A PE2023003030 A PE 2023003030A PE 20240593 A1 PE20240593 A1 PE 20240593A1
Authority
PE
Peru
Prior art keywords
alkyl
effective amount
therapeutically effective
leukemia
menin
Prior art date
Application number
PE2023003030A
Other languages
Spanish (es)
Inventor
Nikki Daskalakis
Christina Diane Guttke
Min Chul Kwon
Lucille Angela Ferrante
Kathryn Elizabeth Packman
Eva Christine Pietsch
Ulrike Philippar
Tinne Ann J Verhulst
Balpreet Bhogal
Yu Sun
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Johannes Wilhelmus J Thuring
Yingtao Liu
Lianzhu Liu
Yanping Xu
Liqiang Fu
Ming Li
Lichao Fang
Xiangjun Deng
Alicia Tee Fuay Ng
Nicolas Freddy J Darville
Vineet Pande
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20240593A1 publication Critical patent/PE20240593A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se refiere a una combinacion que comprende: una cantidad terapeuticamente efectiva de un inhibidor de leucemia de linaje en mezcla de menina 1 (menina-MLL) de Formula I, tautomero, su forma estereoisomerica de este, una sal o un solvato farmaceuticamente aceptable del mismo; una cantidad terapeuticamente efectiva de un inhibidor de linfoma 2 de linfocitos B (BCL-2); y opcionalmente, una cantidad terapeuticamente efectiva de al menos otro agente antineoplasico; en donde R1a representa -C(=O)-NRxaRxb; Het; entre otros; R1b representa F o Cl; Y1 representa -CR5aR5b-, -O- o -NR5c-; R2 se selecciona del grupo que consiste en H, halo, alquilo C1-4, entre otros; U es N o CH; n1, n2, n3 y n4 es cada uno independientemente 1 y 2; X1 representa CH, y X2 representa N; R4 representa isopropilo; R3 representa alquilo-C1-6-NR8aR8b, alquilo-C1-6-C(=O)-NR9aR9b, entre otros. Tambien se refiere a procesos para la preparacion de dichos compuestos, una composicion farmaceutica que comprende dicha combinacion y su uso en la prevencion o el tratamiento de un trastorno hematopoyetico, tales como leucemia con mutacion de nucleofosmina 1 (NPM1), leucemia con reordenamiento de MLL, entre otros.Refers to a combination comprising: a therapeutically effective amount of a menin mixed lineage leukemia inhibitor 1 (menin-MLL) of Formula I, tautomer, its stereoisomeric form thereof, a pharmaceutically acceptable salt or solvate thereof ; a therapeutically effective amount of a B cell lymphoma 2 (BCL-2) inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent; where R1a represents -C(=O)-NRxaRxb; Het; among others; R1b represents F or Cl; Y1 represents -CR5aR5b-, -O- or -NR5c-; R2 is selected from the group consisting of H, halo, C1-4 alkyl, among others; U is N or CH; n1, n2, n3 and n4 are each independently 1 and 2; X1 represents CH, and X2 represents N; R4 represents isopropyl; R3 represents C1-6-alkyl-NR8aR8b, C1-6-alkyl-C(=O)-NR9aR9b, among others. It also refers to processes for the preparation of said compounds, a pharmaceutical composition comprising said combination and its use in the prevention or treatment of a hematopoietic disorder, such as leukemia with nucleophosmin 1 mutation (NPM1), leukemia with MLL rearrangement , among others.

PE2023003030A 2021-05-11 2022-05-09 COMBINATION THERAPIES PE20240593A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CN2021100523 2021-06-17
CN2022086004 2022-04-11
PCT/CN2022/091679 WO2022237720A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (1)

Publication Number Publication Date
PE20240593A1 true PE20240593A1 (en) 2024-03-21

Family

ID=81753154

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003030A PE20240593A1 (en) 2021-05-11 2022-05-09 COMBINATION THERAPIES

Country Status (12)

Country Link
EP (1) EP4337216A1 (en)
JP (1) JP2024518497A (en)
KR (1) KR20240006631A (en)
CN (1) CN117460513A (en)
AU (1) AU2022274071A1 (en)
CA (1) CA3215313A1 (en)
CO (1) CO2023014322A2 (en)
IL (1) IL308335A (en)
PE (1) PE20240593A1 (en)
TW (1) TW202308643A (en)
UY (1) UY39761A (en)
WO (1) WO2022237720A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017007162A (en) 2014-12-18 2017-08-28 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones.
US20190010167A1 (en) * 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
SI3468966T1 (en) * 2016-06-10 2021-03-31 Vitae Pharmaceuticals, Llc Inhibitors of the menin-mll interaction
TW202104207A (en) 2019-04-17 2021-02-01 美商健生生物科技公司 Dihydroorotate dehydrogenase inhibitors
EP4077312A4 (en) 2019-12-19 2024-01-17 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Also Published As

Publication number Publication date
CO2023014322A2 (en) 2023-11-20
TW202308643A (en) 2023-03-01
IL308335A (en) 2024-01-01
KR20240006631A (en) 2024-01-15
CA3215313A1 (en) 2022-11-17
JP2024518497A (en) 2024-05-01
EP4337216A1 (en) 2024-03-20
WO2022237720A1 (en) 2022-11-17
CN117460513A (en) 2024-01-26
UY39761A (en) 2022-11-30
AU2022274071A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
AR120700A1 (en) KRAS G12C INHIBITORS
PE20230376A1 (en) DIACYL GLYCEROL KINASE MODULATING COMPOUNDS
PE20171241A1 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS
PE20151787A1 (en) DERIVATIVES OF 5-PHENOXY-3H-PYRIMIDIN-4-ONA AND THEIR USE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
AR059957A1 (en) DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
AR053364A1 (en) COMPOSITE OF 1H-IMIDAZO 84,5-C) PIRIDIN -2- ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCESS TO PREPARE IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR TREATMENT OF CANCER OR ARTHRITIS
AR017852A1 (en) PIRAZOLO COMPOUNDS (3,4-b) PIRIDINE AND ITS SALTS, USEFUL AS INHIBITORS OF CYCLINE-DEPENDENT PROTEIN-KINASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, EVENTUALLY ASSOCIATED WITH AN ANTI-AGENT AGENT.
HUP0303271A2 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
PE20231304A1 (en) 2,4-DIOXOPYRIMIDINE COMPOUNDS CD73 INHIBITORS
PE20212303A1 (en) AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE IN THE TREATMENT OF CANCER
AR049711A1 (en) HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE
AR048607A1 (en) DERIVATIVES (POLI) AMINOALQUILAMINO ACETAMIDE OF EPIPODOFILOTOXINA, PROCESS OF PREPARATION OF THE SAME AND ITS THERAPEUTIC APPLICATIONS AS ANTICANCEROS AGENTS
JOP20220006A1 (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
AR018330A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE MACROLIDES AS ACTIVE AGENTS FOR THE THERAPY AND PROPHYLAXIS OF SKIN DISEASES
AR065464A1 (en) NICOTINAMIDE DERIVATIVES PHARMACEUTICAL COMPOSITIONS
AR060427A1 (en) AMINO- DERIVATIVES OF ANDROSTANS AND ANDROSTENS AS MEDICATIONS FOR CARDIOVASCULAR DISORDERS
UY26564A1 (en) FACTOR XA INHIBITORS WITH ARYL - AMIDINES AND THEIR DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20210478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
PE20200727A1 (en) HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE
ECSP22040362A (en) 1,2,4OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
PE20240593A1 (en) COMBINATION THERAPIES
ECSP22026478A (en) DIACYLGLYCEROL ACYTRANSFERASE 2 INHIBITOR
AR035970A1 (en) 2-AMINO-BENZOXAZOL SULFONAMID SULFONAMID SPECTRUM OF HIV PROTEASE, PHARMACEUTICAL COMPOSITION, "IN VITRO" METHOD TO INHIBIT THE RETROVIRAL REPLICATION, AND USE OF THESE COMPOUNDS IN THE MANUFACTURE OF MEDICINAL MANUFACTURE
AR107935A1 (en) USE OF COMPOUND 6- (4- (2,3-DIMETHYLPHENOXY) PIPERIDIN-1-IL) METHYL) PYRIMIDINE-2,4 (1H, 3H) -DIONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME TO PREPARE A MEDICINAL, COMBINATION AND COMPOSITION PHARMACEUTICAL UNDERSTANDING SUCH COMPOUND